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Absract: A series of novel β-elemene isopropanolamine derivatives were synthesized 
and evaluated for their antitumor activity. The results indicated that all of the 
compounds showed stronger antiproliferative activities than β-elemene as well as 
improved aqueous solubility. In particular dimer 6q showed the strongest cytotoxicity 
against four tumor cell lines (SGC-7901, HeLa, U87 and A549) with IC50 values 
ranging from 4.37 to 10.20 μM. Moreover, combination of 6q with cisplatin exhibited 
a synergistic effect on these cell lines with IC50 values ranging from 1.21 to 2.94 μM, 
and reversed the resistance of A549/DPP cells with an IC50 value of 2.52 μM. The 
mechanism study revealed that 6q caused cell cycle arrest at the G2 phase and 
induced apoptosis of SGC-7901 cells through a mitochondrial-dependent apoptotic 
pathway. Further in vivo study in H22 liver cancer xenograft mouse model validated 
the antitumor activity of 6q with a tumor inhibitory ratio (TIR) of 60.3%, which was 
higher than that of β-elemene (TIR, 49.1%) at a dose of 60 mg/kg. Altogether, the 
potent antitumor activity of 6q in vitro and in vivo warranted further preclinical 
investigation for potential anticancer chemotherapy. 
 
Key words: β-elemene; isopropanolamine; dimer; antitumor activity; aqueous 
solubility 
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1. Introduction 
Over the past decade, there is a markedly increasing trend in the incidence and 
mortality of malignant tumors around the world [1] and cancer has become the first 
leading cause of death in China, beyond cerebrovascular and heart diseases [2]. The 
extensive prescription of synthetic antitumor drugs is being ruled out owing to their 
toxicity, resistance and unwanted side effects [3,4]. This led to the search for new 
antineoplastic agents, particularly those obtained from natural sources such as 
animals, plants, microbes and marine organisms [5,6]. In recent years, a large number 
of natural products, especially terpenes, have been discovered with marked anticancer 
activity in vitro and in vivo, some of which have been successfully developed for 
clinical use to treat human neoplastic diseases [7-9]. 
Curcuma wenyujin is a popular group of traditional Chinese medicine plants whose 
essential oils are widely used in cancer treatment in China [10]. β-elemene (1, Scheme 
1), a sesquiterpene compound extracted from the essential oils of Curcuma wenyujin, 
accounts for 60-72% of elemene including α, β, γ and δ forms [10]. As the major 
active antitumor component in the elemene mixture, β-elemene has been isolated and 
approved by the Chinese Food and Drug Administration for the treatment of human 
cancers [11]. The major advantages of β-elemene as an anticancer drug are [12-14]: i) 
broad-spectrum antitumor effects in various types of cancers, including drug-resistant 
tumors; ii) not inducing any multidrug resistance and reversing the resistance of other 
antitumor drugs in tumor cells; and iii) low toxicity without bone marrow 
suppression. Despite these striking antitumor properties, the poor water solubility and 
moderate activity of β-elemene hampers its wide applications in clinic. 
Structural modifications are an effective approach to improve the druggability of 
natural compounds [15]. And it has been reported that introduction of oxygen or 
nitrogen-containing polar group into the skeleton of β-elemene could favorably 
impact its water solubility and antitumor activity [16,17]. Enlightened by these 
findings, we designed a series of novel β-elemene isopropanolamine derivatives by 
introducing both amine and hydroxyl groups to increase the water solubility and 
antitumor activity of natural β-elemene. Herein, we report synthesis, in vitro and in 
vivo antitumor activity, and anticancer mechanism for a new class of β-elemene 
isopropanolamine derivatives with improved aqueous solubility. 
 
2. Results and discussions 
2.1. Chemistry 
The synthesis of β-elemene isopropanolamine derivatives 6a-6q was shown in 
Scheme 1. Chlorination of β-elemene (1) with NaClO produced the chlorinated 
mixture of 2a and 2b, followed by treatment with AcONa to give the acylated 
compounds 3a and 3b. The resulting products were subjected to alkaline hydrolysis to 
produce a mixture of 13-β-elemol (4a) and 14-β-elemol (4b), which was separated by 
HPLC to provide the main component 4a [18].
 
Subsequent alkylation of 4a with 
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epibromohydrin in the presence of NaH gave the epoxide intermediate 5, which was 
further reacted with different amines in the presence of a catalytic amount of 
Zn(ClO4)2
.
6H2O to obtain the target compounds 6a-6q [19]. 
 
 
Scheme 1. Synthetic routes of the title compounds 6a-6q. Reagents and conditions: (a) NaClO, 
HOAc/CH2Cl2, 0~5 
o
C, 6 h, 55%; (b) DMF, NaOAc, 120 
o
C, 8 h, 75%; (c) MeOH/CHCl3, KOH, 
reflux, 2 h, 85%; (d) Separated by HPLC, Hexane/EtOH = 98/2 (V/V), UV = 214 nm; (e) 
epibromohydrin, NaH, anhydrous DMF, rt, 3 h, 72%; (f) amines, Cat. Zn(ClO4)2
.
6H2O, 80 
o
C, 1 h, 
58-84%. 
2.2. Pharmacology 
2.2.1. In vitro antiproliferative activity 
Initially, β-elemene isopropanolamine derivatives 6a-6q were examined for their 
antiproliferative activities against three cancer cell lines (SGC-7901: human gastric 
carcinoma; HeLa: human cervical adenocarcinoma; U87: human glioblastoma). As 
shown in Table 1, all of the derivatives exhibited stronger activities than parent 
compound β-elemene, and some of them even showed preferable activities than 
positive control cisplatin, suggesting that introduction of an isopropanolamine moiety 
was beneficial for the antitumor activity of β-elemene. Aliphatic (6a), naphthenic 
(6b-6g) and aryl (6h-6n) amines showed nearly the same activity, approximately 3- to 
-10 fold more potent than β-elemene. When R was benzylamine (6o) or 
phenoxyethylamine (6p), the activity was markedly improved with IC50 values of 
10~20 μM on all tested cell lines. It is surprising that among these compounds, the 
dimer derivative 6q exhibited the strongest activity with IC50 values of 4.37, 7.56 and 
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10.20 μM against SGC-7901, HeLa and U87 cell lines, respectively, which was 
superior to cisplatin with IC50 values of 9.09, 16.28 and 21.39 μM, respectively. 
Table 1. Antiproliferative activities of β-elemene isopropanolamine derivatives 
against three cancer cell lines 
Compd 
Cell lines (IC50
a
,
 
μM) 
SGC-7901 HeLa U87 
β-Elemene 236.27 ± 18.41 213.51 ± 15.23 179.72 ± 15.37 
6a 43.32 ± 3.78 36.26 ± 3.86 49.00 ± 5.44 
6b 42.86 ± 4.43 29.96 ± 1.89 35.02 ± 3.92 
6c 24.33 ± 2.67 29.45 ± 3.95 37.93 ± 3.08 
6d 44.87 ± 5.54 52.29 ± 4.72 39.07 ± 2.58 
6e 31.25 ± 2.47 26.42 ± 0.87 23.99 ± 1.69 
6f 37.75 ± 1.55 31.81 ± 2.98 38.20 ± 5.14 
6g 49.23 ± 1.82 20.79 ± 3.43 22.12 ± 0.96 
6h 56.76 ± 4.29 55.77 ± 6.17 56.36 ± 3.63 
6i 34.42 ± 2.86 41.19 ± 3.74 38.92 ± 4.51 
6j 51.89 ± 5.89 37.95 ± 3.28 66.05 ± 5.43 
6k 26.41 ± 1.09 22.67 ± 1.65 28.50 ± 2.83 
6l 65.16 ± 5.13 39.88 ± 4.78 54.86 ± 3.62 
6m 50.27 ± 4.42 66.53 ± 3.21 61.47 ± 6.46 
6n 36.49 ± 3.63 35.49 ± 1.03 57.41 ± 5.86 
6o 21.40 ± 1.22 10.04 ± 0.52 12.63 ± 1.04 
6p 15.40 ± 1.67 9.42 ± 0.73 10.50 ± 0.91 
6q 4.37 ± 0.51 7.56 ± 0.65 10.20 ± 0.76 
Cisplatin 9.09 ± 0.83 16.28 ± 1.06 21.39 ± 1.91 
a
 IC50: concentration of the test compound that inhibits 50% of cell growth.
 
Results are expressed 
as the mean ± SD (n = 3). 
 
2.2.2. In vitro antiproliferative activity of 6q in combination with cisplatin 
It was reported that β-elemene increased the sensitivity of several cancer cells and 
even reversed the resistance to cisplatin [20-24]. In order to investigate whether 6q 
could induce sensitization to cisplatin, an equimolar combination of 6q with cisplatin 
was examined for the antiproliferative activity against SGC-7901, HeLa, U87, A549 
(human lung adenocarcinoma) and A549/DDP (cisplatin-resistant human lung 
adenocarcinoma) cells. As presented in Table 2, combination of 6q and cisplatin 
exhibited a synergistic cytotoxicity effect on SGC-7901, HeLa, U87 and A549 cells 
with IC50 values of 1.21, 2.94, 1.68 and 2.37 μM, respectively. Particularly on U87 
cells, this combination was 6-fold or 13-fold more potent than 6q or cisplatin, 
respectively. In addition, 6q showed potent activity against A549/DDP cells with an 
IC50 value of 10.91 μM and the combination led to a reversal of resistance of 
A549/DPP cells with an IC50 value of 2.52 μM. 
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Table 2. Antiproliferative activity of 6q and DDP alone or in combination against five 
cancer cell lines 
Compd 
Cell lines (IC50
a
, μM) 
SGC-7901 HeLa U87 A549 A549/DDP 
6q 4.37 ± 0.51 7.56 ± 0.65 10.20 ± 0.76 9.28 ± 0.68 10.91 ± 0.84 
DDP
b
 9.09 ± 0.83 16.28 ± 1.06 21.39 ± 1.91 9.54 ± 0.87 47.90 ± 5.63 
6q + DDP 1.21 ± 0.13 2.94 ± 0.24 1.68 ± 0.09 2.37 ± 0.21 2.52 ± 0.18 
a 
IC50: concentration of the test compound that inhibits 50% of cell growth. Results are expressed 
as the mean ± SD (n =3). 
b
 DDP: cisplatin. 
2.2.3. Compound 6q induces cell cycle arrest  
To determine whether the suppression of cell growth by 6q is caused by a cell-cycle 
effect, the DNA content of cell nuclei was analyzed by flow cytometry (Figure 1). 
SGC-7901 cells were treated with 6q at concentrations of 1.0, 2.0 and 4.0 μM, which 
resulted in accumulation of 33.12%, 44.04%, and 59.93% of cells at the G2 phase, 
respectively. Meanwhile, the percentage of cells at the G1 phase decreased to 38.77%, 
32.09%, and 19.17%, respectively. These results indicated that 6q caused G2-phase 
arrest of the cell cycle in inhibition of cell growth. 
 
Figure 1. Compound 6q induces G2-phase arrest in SGC-7901 cells. SGC-7901 cells were treated 
with varying concentrations of 6q (0, 1.0, 2.0, 4.0 μM) for 72 h and stained with PI. The cell cycle 
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distributions were analyzed by flow cytometry. 
2.2.4. Compound 6q induces apoptosis 
To clarify whether the loss of cancer cell viability promoted by 6q is associated 
with apoptosis, an Annexin V-APC/7-AAD binding assay was performed. As shown in 
Figure 2, 6q significantly induced apoptosis in a dose-dependent manner. Treatment 
of SGC-7901 cells with 6q at 1.0, 2.0 and 4.0 μM for 72 h resulted in 22.13%, 
39.37% and 59.08% apoptotic cells (Q2 + Q4), as compared with 6.46% in an 
untreated vehicle control, suggesting that 6q exerted its antitumor effect possibly by 
inducing apoptosis.  
 
Figure 2. Compound 6q induces apoptosis of SGC-7901 cells. Treatment with 6q (0, 1.0, 2.0, 4.0 
μM) for 72 h, SGC-7901 cells were collected and stained with Annexin V-APC/7-AAD, followed 
by flow cytometric analysis. 
2.2.5. Compound 6q induces mitochondrial depolarization 
To examine whether cell apoptosis induced by 6q is related to the decline of 
mitochondrial membrane potential, the lipophilic mitochondrial probe JC-1 staining 
assay was carried out. When SGC-7901 cells were treated with 6q at concentrations 
of 1.0, 2.0 and 4.0 μM, the number of cells with collapsed mitochondrial membrane 
potentials increased to 8.56%, 19.07%, and 33.94%, respectively (Figure 3). These 
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results demonstrated that 6q caused mitochondrial depolarization of SGC-7901 cells 
in the process of apoptosis. 
 
Figure 3. Compound 6q induces mitochondrial depolarization in SGC-7901 cells. Incubation with 
different concentrations (0, 1.0, 2.0, 4.0 μM) of 6q in SGC-7901 cells for 72h prior to staining 
with JC-1 dye, the number of cells with collapsed mitochondrial membrane potentials was 
determined by flow cytometry analysis. 
2.2.6. Effect of 6q on apoptosis-related proteins 
A decline in mitochondrial membrane potential is associated with cytochrome C. 
When the structure of the membrane is damaged, mitochondrial membrane 
permeability increases, cytochrome C releases into the cytoplasm across the 
membrane, which leads to mitochondrial depolarization [20]. Meanwhile, the release 
of cytochrome C promotes the formation of a caspase activating complex that 
contains cytochrome C, Apaf-1 and procaspase-9. This apoptosome complex triggers 
the activation of caspase-9, which leads to a proteolytic cascade that activates 
downstream effector caspases, including caspase-3, -6 and -7 [25]. These caspases are 
the final executors of the apoptotic process, and the apoptotic pathway is activated 
through the cleavage of PARP [26,27]. Bcl-2 plays a pivotal protective role by 
preserving mitochondrial structure and function. Bax, a dominant-negative inhibitor 
of Bcl-2, induces a mitochondrial permeability transition and promotes apoptosis [28]. 
As shown in Figure 4, treatment with 6q in SGC-7901 cells led to enhancement of 
cytochrome C release, activation of caspase-3 and -9, cleavage of PARP, 
downregulation of Bcl-2 expression and upregulation of Bax expression in a 
concentration-dependent manner. The results indicate that the antitumor effect of 6q 
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may be mediated via a mitochondrial-dependent apoptotic pathway. 
 
 
Figure 4. Effects of 6q on apoptosis-related proteins in SGC-7901 cells. SGC-7901 cells were 
exposed to 6q at 0, 1.0, 2.0 and 4.0 μM for 72 h. A total of 25 μg of cellular proteins extracted 
from 6q-treated cells were separated by SDS-PAGE, transferred to a nitrocellulose membrane and 
immunoblotted with antibodies against Bcl-2, Bax, cytochrome C, caspase-9, caspase-3 and PARP. 
GAPDH antibody was used as a loading control. Cytochrome C (M): mitochondrial cytochrome 
C; cytochrome C (C): cytosolic cytochrome C. 
2.2.7. Determination of water solubility  
The poor aqueous solubility of β-elemene is one of the main factors that limit its 
clinical application. In order to verify whether the aqueous solubility of β-elemene 
was improved, representative compounds 6a and 6q were selected to determine their 
water solubility by the HPLC method [29]. As expected, incorporating an 
isopropanolamine moiety into β-elemene not only enhanced the antiproliferative 
activity but also significantly improved their aqueous solubility. The water solubility 
of 6a and 6q was 1.18 and 0.27 mg/mL, respectively, which was markedly higher 
than that of β-elemene (not detected). 
2.2.8. In vivo antitumor activity of 6q 
Based on the above results, we further tested the in vivo antitumor activity of 6q in 
the mice bearing with H22 liver cancer. 32 mice were randomly assigned to four 
groups and intravenously administered with 60 mg/kg β-elemene, 30 or 60 mg/kg 6q 
in a vehicle of 10% DMF/2% Tween 80/88% saline once a day, respectively. The 
mice were sacrificed after 21 days, and the tumors were excised and weighed. As 
illustrated in Table 3, 6q showed potent antitumor activity in vivo in a dose-dependent 
manner. At a dose of 60 mg/kg, 6q possessed a tumor inhibitory rate (TIR) of 60.3%, 
which was significantly superior to β-elemene with a TIR of 49.1%. Thus, 6q is 
worthy of further investigation as a potential anticancer drug candidate. 
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Table 3. In vivo antitumor activity of 6q against mice bearing H22 liver cancer 
Drugs 
Dose 
mg/k
g 
Number of 
mice  
Weight of mice (g) 
 
Weight of 
tumor X ± 
SD (g) 
 
Ratio of 
inhibition 
(%) Start End Start End 
Control
a
 - 8 8  18.2 ± 0.3 26.0 ± 0.6  4.38 ± 0.16  / 
β-Elemene 60 8 8  18.4 ± 0.2 25.4 ± 0.5  2.23 ± 0.18**  49.1% 
6q 
30 8 8  18.2 ± 0.1 25.7 ± 0.5  2.34 ± 0.17
**
  46.6% 
60 8 8  18.3 ± 0.3 25.3 ± 0.4  1.74 ± 0.13
**
  60.3% 
a
vehicle of 10% DMF/2% Tween 80/88% saline. **P < 0.01 vs. control group. 
3. Conclusion 
In summary, a series of novel β-elemene derivatives hybridizing isopropanolamine 
moieties were synthesized with improved aqueous solubility. The bioassay results 
indicated that all of the derivatives exhibited more potent antiproliferative activities 
than parent compound β-elemene. Among them, the dimer compound 6q showed the 
strongest activity against SGC-7901, HeLa, U87 and A549 cell lines, which were 
superior to that of positive control cisplatin. Interestingly, combination of 6q with 
cisplatin exhibited a synergistic effect on these cell lines and reversed the resistance 
of A549/DPP cells. Further mechanism studies revealed that 6q caused cell cycle 
arrest at the G2 phase and induced apoptosis of SGC-7901 cells by a 
mitochondrial-dependent apoptotic pathway. Moreover, the in vivo antitumor activity 
of 6q was validated in H22 liver cancer xenograft mouse model. Collectively, the 
current study may provide a new insight for the design of natural product-like drug 
candidates to enhance the efficacy of chemotherapy. 
4. Experimental  
4.1. Chemistry 
Most chemicals and solvents were purchased from commercial sources. Further 
purification and drying by standard methods were employed when necessary. 
1
H 
NMR and 
13
C NMR spectra were recorded on Bruker-300 spectrometers in the 
indicated solvents (TMS as internal standard). Data are reported as follows: chemical 
shift in ppm (δ), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, brs = 
broad singlet, m = multiplet), coupling constant (Hz), and integration. High 
Resolution Mass measurement was performed on Agilent QTOF 6520 mass 
spectrometer with electron spray ionization (ESI) as the ion source. Purity of all tested 
compounds was ≥ 95%, as estimated by HPLC analysis. Flash column 
chromatography was carried out using commercially available silica gel (200-300 
mesh) under pressure.  
4.1.1. Synthesis of intermediate 4a [18] 
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To a solution of β-elemene (4.08 g, 20.0 mmol) in glacial acetic acid, 1.60 N 
sodium hypochlorite (16.9 mL, 27.0 mmol) was added over 2 h period under stirring 
at 0~5
 o
C, then the mixture was kept stirring for another 4 h and extracted with 
CH2Cl2. The combined organic extracts were washed with water, dried over 
anhydrous Na2SO4, and filtered. The filtrate was concentrated, and the residue was 
purified by flash column chromatography using petroleum ether as an eluent to give 
the mixture of 2a and 2b as yellowish liquid, yield 55%. 
A mixture of 2a and 2b (2.38 g, 10.0 mmol), and anhydrous AcONa (2.46 g, 20 
mmol) were added in anhydrous DMF, and stirred under 120 
o
C for 8 h. The solution 
was filtered and the filtrate was diluted with CH2Cl2, washed with water, dried over 
anhydrous Na2SO4, concentrated successively. The residue was purified by flash 
column chromatography using petroleum ether/ethyl acetate (30/1, V/V) as an eluent 
to provide the mixture of 3a and 3b as colorless liquid, yield 75%. 
A mixture of 3a and 3b (1.83 g, 7.0 mmol), and KOH (785.4 mg, 14 mmol) were 
added in a mixture solution of methanol and chloroform (1:1, V/V), and stirred under 
reflux for 2 h. The solution was filtered and concentrated, and the residue was purified 
by flash column chromatography using petroleum ether/ethyl acetate (10/1, V/V) as 
an eluent to give the mixture of 4a and 4b (1.31 g, 85%), which was further separated 
by HPLC (CHIRALPAK AD-H, Hexane : EtOH = 98 : 2, 1.0 mL·min
-1
, UV = 214 nm) 
to afford pure 4a as colorless liquid, yield 66.4%. 
13-β-elemol (4a): 1H NMR (300 MHz, CDCl3) δ 5.81 (dd, J1 = 17.8 Hz, J2 = 10.5 
Hz, 1H), 5.05 (d, J = 1.3 Hz, 1H), 4.91-4.94 (m, 2H), 4.88 (s, 1H), 4.82 (t, J = 1.7 Hz, 
1H), 4.59 (s, 1H), 4.13 (s, 2H), 1.97-2.05 (m, 2H), 1.71 (s, 3H), 1.41-1.67 (m, 6H), 
1.01 (s, 3H); 
13
C NMR (75 MHz, CDCl3) δ 153.7, 150.0, 147.4, 112.1, 109.9, 107.9, 
65.1, 52.7, 41.4, 39.8, 39.7, 33.2, 27.2, 24.7, 16.5; HRMS (ESI) calcd for C15H25O 
[M+H]
+
: 221.1900, found 221.1901. 
4.1.2. General procedure for synthesis of compounds 6a-6q 
To a solution of 4a (88 mg, 0.4 mmol) in anhydrous DMF (5 mL) was added NaH 
(60%, 0.6 mmol, 25 mg) at room temperature for 30 min, epibromohydrin (66 mg, 
0.48 mmol) was then added and stirred for another 2.5 h. The reaction mixture was 
quenched with 5 mL water and extracted with ethyl acetate (10 mL × 3). The 
combined organic extracts were washed with water (5 mL × 2), dried over anhydrous 
Na2SO4, and filtered. The filtrate was concentrated and purified by flash column 
chromatography using petroleum ether/ethyl acetate (30/1, V/V) as an eluent to give 
intermediate 5 as colorless liquid, yield 72%. 
2-(((2-((1R,3S,4S)-4-methyl-3-(prop-1-en-2-yl)-4-vinylcyclohexyl)allyl)oxy)methy
l)oxirane (5): 
1
H NMR (300 MHz, CDCl3) δ 5.82 (dd, J = 17.8, 10.5 Hz, 1H), 5.05 (d, 
J = 1.0 Hz, 1H), 4.98 (s, 1H), 4.92 (dd, J = 5.4, 1.2 Hz, 1H), 4.88 (s, 1H), 4.82 (s, 
1H), 4.59 (s, 1H), 4.11 – 3.96 (m, 2H), 3.71 (dd, J = 11.5, 3.0 Hz, 1H), 3.38 (dd, J = 
11.5, 5.8 Hz, 1H), 3.21 – 3.11 (m, 1H), 2.85 – 2.78 (m, 1H), 2.62 (dd, J = 5.0, 2.7 Hz, 
1H), 2.12 – 1.96 (m, 2H), 1.71 (s, 3H), 1.69 – 1.55 (m, 3H), 1.53 – 1.42 (m, 3H), 1.01 
(s, 3H); 
13
C NMR (75 MHz, CDCl3) δ 149.73, 149.67, 147.08, 111.65, 109.98, 
109.43, 73.08, 70.09, 52.22, 50.35, 43.82, 40.80, 39.41, 39.31, 32.64, 26.57, 24.33, 
16.08. 
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5 (55 mg, 0.2 mmol), corresponding amines (0.6 mmol for 6a-6p, 0.1 mmol for 6q) 
and Zn(ClO4)2
.
6H2O (1 mg) were added in a 10 mL sealed tube and vigorously stirred 
at 80 °C for 1 h. Afterward it was cooled to ambient temperature, 5 mL water and 10 
mL dichloromethane were added. The organic layer was washed with brine, dried 
over anhydrous Na2SO4, and concentrated successively. The obtained residue was 
purified with flash column chromatography using dichloromethane/methanol 
(100/1~40/1, V/V) as an eluent to give the title compounds as yellowish liquid, yield 
58-84%. 
1-(Diethylamino)-3-((2-((1R,3S,4S)-4-methyl-3-(prop-1-en-2-yl)-4-vinylcyclohexyl
)allyl)oxy)propan-2-ol (6a): 
1
H NMR (300 MHz, CDCl3) δ 5.75 (dd, J = 17.8, 10.5 
Hz, 1H), 4.94 (s, 1H), 4.91 (s, 1H), 4.85 (d, J = 3.8 Hz, 1H), 4.81 (s, 1H), 4.75 (s, 1H), 
4.51 (s, 1H), 4.25 – 4.12 (m, 2H), 4.02 – 3.86 (m, 2H), 3.58 – 3.41 (m, 2H), 3.38 – 
3.21 (m, 4H), 3.20 – 3.14 (m, 2H), 2.02 – 1.84 (m, 2H), 1.64 (s, 3H), 1.63 – 1.49 (m, 
3H), 1.48 – 1.28 (m, 9H), 0.93 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 149.55, 149.30, 
147.06, 111.67, 110.06, 109.52, 73.29, 70.93, 64.45, 55.21, 52.13, 48.32, 40.92, 39.34, 
39.27, 32.68, 26.59, 24.35, 16.06, 8.31; HRMS (ESI) calculated for C22H40NO2 [M + 
H]
+
 350.3054, found 350.3052. 
1-((2-((1R,3S,4S)-4-Methyl-3-(prop-1-en-2-yl)-4-vinylcyclohexyl)allyl)oxy)-3-(pyr
rolidin-1-yl)propan-2-ol (6b): 
1
H NMR (300 MHz, CDCl3) δ 5.82 (dd, J = 17.8, 10.5 
Hz, 1H), 5.02 (s, 1H), 4.98 (s, 1H), 4.92 (d, J = 3.9 Hz, 1H), 4.88 (s, 1H), 4.82 (s, 1H), 
4.58 (s, 1H), 4.38 (brs, 1H), 4.25 – 4.12 (m, 1H), 4.07 – 3.93 (m, 2H), 3.75 – 3.12 (m, 
8H), 2.27 – 2.09 (m, 4H), 2.06 – 1.87 (m, 2H), 1.71 (s, 3H), 1.68 – 1.50 (m, 3H), 1.52 
– 1.30 (m, 3H), 1.00 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 149.56, 149.34, 147.09, 
111.67, 109.97, 109.53, 73.22, 70.94, 65.52, 58.18, 54.98, 52.11, 40.88, 39.34, 39.28, 
32.66, 26.58, 24.36, 22.49, 16.06; HRMS (ESI) calculated for C22H38NO2 [M + H]
+
 
348.2897, found 348.2899. 
1-((2-((1R,3S,4S)-4-Methyl-3-(prop-1-en-2-yl)-4-vinylcyclohexyl)allyl)oxy)-3-(pip
eridin-1-yl)propan-2-ol (6c): 
1
H NMR (300 MHz, CDCl3) δ 5.82 (dd, J = 17.8, 10.5 
Hz, 1H), 5.02 (s, 1H), 4.98 (s, 1H), 4.92 (d, J = 4.0 Hz, 1H), 4.88 (s, 1H), 4.82 (s, 1H), 
4.58 (s, 1H), 4.38 (s, 1H), 4.30 – 4.20 (m, 1H), 4.08 – 3.94 (m, 2H), 3.57 – 3.44 (m, 
2H), 3.33 – 3.08 (m, 6H), 2.08 – 1.81 (m, 6H), 1.71 (s, 3H), 1.69 – 1.54 (m, 5H), 1.53 
– 1.41 (m, 3H), 1.00 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 149.58, 149.41, 147.08, 
111.66, 110.01, 109.50, 73.24, 71.25, 64.48, 60.21, 54.25, 52.14, 40.86, 39.35, 39.29, 
32.65, 26.56, 24.35, 22.99, 21.60, 16.06; HRMS (ESI) calculated for C23H40NO2 [M + 
H]
+
 362.3054, found 362.3057. 
1-((2-((1R,3S,4S)-4-Methyl-3-(prop-1-en-2-yl)-4-vinylcyclohexyl)allyl)oxy)-3-mor
pholinopropan-2-ol (6d): 
1
H NMR (300 MHz, CDCl3) δ 5.75 (dd, J = 17.8, 10.5 Hz, 
1H), 4.96 (s, 1H), 4.90 (s, 1H), 4.85 (d, J = 3.9 Hz, 1H), 4.81 (s, 1H), 4.75 (s, 1H), 
4.51 (s, 1H), 4.04 – 3.89 (m, 2H), 3.88 – 3.80 (m, 1H), 3.73 – 3.60 (m, 4H), 3.42 – 
3.31 (m, 2H), 2.63 – 2.49 (m, 2H), 2.47 – 2.31 (m, 4H), 2.05 – 1.88 (m, 2H), 1.64 (s, 
3H), 1.62 – 1.47 (m, 3H), 1.46 – 1.34 (m, 3H), 0.94 (s, 3H); 13C NMR (75 MHz, 
CDCl3) δ 149.79, 149.62, 147.03, 111.66, 109.89, 109.44, 73.30, 71.80, 66.41, 65.49, 
60.88, 53.26, 52.28, 40.89, 39.41, 39.28, 32.66, 26.56, 24.30, 16.11; HRMS (ESI) 
calculated for C22H38NO3 [M + H]
+
 364.2846, found 364.2843. 
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1-((2-((1R,3S,4S)-4-Methyl-3-(prop-1-en-2-yl)-4-vinylcyclohexyl)allyl)oxy)-3-(4-
methylpiperazin-1-yl)propan-2-ol (6e): 
1
H NMR (300 MHz, CDCl3) δ 5.74 (dd, J = 
17.8, 10.5 Hz, 1H), 4.95 (s, 1H), 4.90 (s, 1H), 4.85 (d, J = 4.0 Hz, 1H), 4.80 (s, 1H), 
4.75 (s, 1H), 4.51 (s, 1H), 4.04 – 3.89 (m, 2H), 3.88 – 3.80 (m, 1H), 3.44 – 3.27 (m, 
2H), 3.10 (s, 1H), 2.65 (s, 2H), 2.55 – 2.32 (m, 8H), 2.26 (s, 3H), 2.02 – 1.88 (m, 2H), 
1.63 (s, 3H), 1.61 – 1.50 (m, 3H), 1.46 – 1.35 (m, 3H), 0.93 (s, 3H); 13C NMR (75 
MHz, CDCl3) δ 149.80, 149.63, 147.04, 111.65, 109.86, 109.42, 73.27, 71.86, 65.65, 
60.16, 54.43, 52.26, 52.26, 45.26, 40.86, 39.41, 39.28, 32.65, 26.55, 24.30, 16.10; 
HRMS (ESI) calculated for C23H41N2O2 [M + H]
+
 377.3163, found 377.3167. 
Furan-2-yl(4-(2-hydroxy-3-((2-((1R,3S,4S)-4-methyl-3-(prop-1-en-2-yl)-4-vinylcyc
lohexyl)allyl)oxy)propyl)piperazin-1-yl)methanone (6f): 
1
H NMR (300 MHz, CDCl3) 
δ 7.42 (s, 1H), 6.94 (d, J = 3.4 Hz, 1H), 6.42 (dd, J = 3.3, 1.7 Hz, 1H), 5.74 (dd, J = 
17.8, 10.5 Hz, 1H), 4.96 (s, 1H), 4.91 (s, 1H), 4.86 (d, J = 3.5 Hz, 1H), 4.81 (s, 1H), 
4.75 (s, 1H), 4.51 (s, 1H), 4.02 – 3.85 (m, 3H), 3.80 (s, 4H), 3.44 – 3.32 (m, 2H), 2.74 
– 2.63 (m, 2H), 2.59 – 2.39 (m, 4H), 2.02 – 1.86 (m, 2H), 1.64 (s, 3H), 1.62 – 1.46 (m, 
3H), 1.45 – 1.33 (m, 3H), 0.94 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 158.51, 149.71, 
149.61, 147.06, 143.26, 116.15, 111.68, 110.85, 109.97, 109.49, 73.32, 71.64, 65.68, 
60.45, 52.95, 52.26, 40.88, 39.41, 39.30, 32.66, 26.56, 24.33, 16.10; HRMS (ESI) 
calculated for C27H41N2O4 [M + H]
+
 457.3061, found 457.3060. 
1-(4-(Hydroxymethyl)piperidin-1-yl)-3-((2-((1R,3S,4S)-4-methyl-3-(prop-1-en-2-yl
)-4-vinylcyclohexyl)allyl)oxy)propan-2-ol (6g): 
1
H NMR (300 MHz, CDCl3) δ 5.82 
(dd, J = 17.7, 10.6 Hz, 1H), 5.02 (s, 1H), 4.97 (s, 1H), 4.92 (d, J = 3.9 Hz, 1H), 4.88 
(s, 1H), 4.82 (s, 1H), 4.58 (s, 1H), 4.15 – 3.93 (m, 3H), 3.63 (brs, 2H), 3.55 – 3.32 (m, 
4H), 3.23 (d, J = 11.1 Hz, 1H), 3.12 (d, J = 11.4 Hz, 1H), 2.75 – 2.55 (m, 2H), 2.45 (t, 
J = 10.9 Hz, 1H), 2.22 (t, J = 10.9 Hz, 1H), 2.06 – 1.92 (m, 2H), 1.81 (d, J = 12.4 Hz, 
2H), 1.71 (s, 3H), 1.68 – 1.54 (m, 4H), 1.53 – 1.34 (m, 5H), 1.00 (s, 3H); 13C NMR 
(75 MHz, CDCl3) δ 149.74, 149.63, 147.05, 111.66, 109.80, 109.44, 73.24, 71.82, 
66.52, 65.24, 60.73, 54.54, 52.25, 52.09, 40.88, 39.41, 39.29, 37.21, 32.67, 27.58, 
27.39, 26.56, 24.31, 16.10; HRMS (ESI) calculated for C24H42NO3 [M + H]
+
 
392.3159, found 392.3164. 
1-((2-((1R,3S,4S)-4-Methyl-3-(prop-1-en-2-yl)-4-vinylcyclohexyl)allyl)oxy)-3-(phe
nylamino)propan-2-ol (6h): 
1
H NMR (300 MHz, CDCl3) δ 7.10 (t, J = 7.8 Hz, 2H), 
6.66 (t, J = 7.3 Hz, 1H), 6.59 (d, J = 7.9 Hz, 2H), 5.73 (dd, J = 17.8, 10.5 Hz, 1H), 
4.96 (s, 1H), 4.92 (s, 1H), 4.85 (d, J = 3.6 Hz, 1H), 4.80 (s, 1H), 4.75 (s, 1H), 4.51 (s, 
1H), 4.06 – 3.87 (m, 3H), 3.50 – 3.31 (m, 2H), 3.24 (dd, J = 12.7, 4.2 Hz, 1H), 3.09 
(dd, J = 12.7, 7.2 Hz, 1H), 2.02 – 1.92 (m, 2H), 1.63 (s, 3H), 1.62 – 1.45 (m, 3H), 
1.44 – 1.33 (m, 3H), 0.93 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 150.09, 148.00, 
147.54, 129.30, 118.05, 113.40, 112.23, 110.58, 110.36, 110.02, 73.77, 72.28, 69.04, 
52.74, 47.01, 41.41, 39.90, 39.81, 33.19, 27.11, 24.85, 16.61; HRMS (ESI) calculated 
for C24H36NO2 [M + H]
+
 370.2741, found 370.2743. 
1-((2-Chlorophenyl)amino)-3-((2-((1R,3S,4S)-4-methyl-3-(prop-1-en-2-yl)-4-vinylc
yclohexyl)allyl)oxy)propan-2-ol (6i): 
1
H NMR (300 MHz, CDCl3) δ 7.23 – 7.15 (m, 
1H), 7.06 (t, J = 7.7 Hz, 1H), 6.65 – 6.51 (m, 2H), 5.73 (dd, J = 17.8, 10.5 Hz, 1H), 
4.97 (s, 1H), 4.92 (s, 1H), 4.85 (d, J = 3.2 Hz, 1H), 4.80 (s, 1H), 4.75 (s, 1H), 4.51 (s, 
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1H), 4.07 – 3.85 (m, 3H), 3.53 – 3.38 (m, 2H), 3.29 (dd, J = 12.8, 4.6 Hz, 1H), 3.16 
(dd, J = 12.8, 6.8 Hz, 1H), 2.06 – 1.84 (m, 2H), 1.63 (s, 3H), 1.60 – 1.45 (m, 3H), 
1.44 – 1.27 (m, 3H), 0.93 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 149.59, 147.04, 
143.48, 136.87, 128.74, 127.31, 119.15, 117.16, 111.72, 111.00, 110.22, 109.51, 
73.29, 71.55, 68.42, 52.22, 46.03, 40.87, 39.40, 39.31, 32.67, 26.60, 24.37, 16.10; 
HRMS (ESI) calculated for C24H35ClNO2 [M + H]
+
 404.2351, found 404.2349. 
1-((2-Methoxyphenyl)amino)-3-((2-((1R,3S,4S)-4-methyl-3-(prop-1-en-2-yl)-4-vin
ylcyclohexyl)allyl)oxy)propan-2-ol (6j): 
1
H NMR (300 MHz, CDCl3) δ 6.89 (t, J = 
7.6 Hz, 1H), 6.80 (d, J = 7.4 Hz, 1H), 6.70 (dd, J = 15.9, 7.7 Hz, 2H), 5.84 (dd, J = 
17.7, 10.5 Hz, 1H), 5.08 (s, 1H), 5.02 (s, 1H), 4.96 (d, J = 3.7 Hz, 1H), 4.91 (s, 1H), 
4.86 (s, 1H), 4.62 (s, 1H), 4.22 – 3.97 (m, 3H), 3.88 (s, 3H), 3.63 – 3.47 (m, 2H), 3.47 
– 3.29 (m, 1H), 3.22 (dd, J = 12.8, 7.1 Hz, 1H), 2.65 (brs, 1H), 2.12 – 1.94 (m, 2H), 
1.74 (s, 3H), 1.73 – 1.57 (m, 3H), 1.56 – 1.40 (m, 3H), 1.04 (s, 3H); 13C NMR (75 
MHz, CDCl3) δ 150.23, 150.14, 147.55, 147.12, 138.08, 121.25, 116.97, 112.22, 
110.48, 110.19, 110.00, 109.53, 73.72, 72.28, 69.17, 55.41, 52.73, 46.66, 41.39, 39.92, 
39.82, 33.18, 27.11, 24.87, 16.61; HRMS (ESI) calculated for C25H38NO3 [M + H]
+
 
400.2846, found 400.2841. 
1-((2-((1R,3S,4S)-4-Methyl-3-(prop-1-en-2-yl)-4-vinylcyclohexyl)allyl)oxy)-3-((4-
nitrophenyl)amino)propan-2-ol (6k): 
1
H NMR (300 MHz, CDCl3) δ 8.02 (d, J = 8.9 
Hz, 2H), 6.51 (d, J = 9.0 Hz, 2H), 5.74 (dd, J = 17.8, 10.5 Hz, 1H), 4.97 (s, 1H), 4.95 
(s, 1H), 4.86 (d, J = 2.2 Hz, 1H), 4.81 (d, J = 2.7 Hz, 1H), 4.76 (s, 1H), 4.51 (s, 1H), 
4.10 – 3.91 (m, 3H), 3.56 – 3.38 (m, 2H), 3.37 – 3.27 (m, 1H), 3.20 (dd, J = 12.8, 7.1 
Hz, 1H), 2.05 – 1.86 (m, 2H), 1.64 (s, 3H), 1.62 – 1.44 (m, 3H), 1.43 – 1.32 (m, 3H), 
0.94 (s, 3H); 
13
C NMR (75 MHz, CDCl3) δ 153.23, 149.94, 149.90, 147.49, 134.90, 
126.41, 112.25, 111.45, 110.86, 110.11, 73.89, 71.82, 68.74, 52.75, 46.09, 41.49, 
39.86, 39.78, 33.22, 27.11, 24.84, 16.60; HRMS (ESI) calculated for C24H35N2O4 [M 
+ H]
+
 415.2591, found 415.2594. 
1-((4-Bromophenyl)amino)-3-((2-((1R,3S,4S)-4-methyl-3-(prop-1-en-2-yl)-4-vinylc
yclohexyl)allyl)oxy)propan-2-ol (6l): 
1
H NMR (300 MHz, CDCl3) δ 7.18 (d, J = 8.5 
Hz, 2H), 6.47 (d, J = 8.7 Hz, 2H), 5.74 (dd, J = 17.8, 10.5 Hz, 1H), 4.96 (s, 1H), 4.92 
(s, 1H), 4.86 (d, J = 2.6 Hz, 1H), 4.81 (d, J = 2.0 Hz, 1H), 4.76 (s, 1H), 4.51 (s, 1H), 
3.94 (s, 3H), 3.51 – 3.34 (m, 2H), 3.30 – 3.11 (m, 2H), 3.06 (dd, J = 12.6, 7.2 Hz, 1H), 
2.02 – 1.88 (m, 2H), 1.63 (s, 3H), 1.61 – 1.46 (m, 3H), 1.45 – 1.33 (m, 3H), 0.93 (s, 
3H); 
13
C NMR (75 MHz, CDCl3) δ 149.58, 149.53, 147.01, 146.37, 131.49, 116.41, 
114.54, 111.74, 110.15, 109.55, 73.29, 71.66, 68.39, 52.26, 46.57, 40.95, 39.39, 39.28, 
32.70, 26.62, 24.33, 16.12; HRMS (ESI) calculated for C24H35BrNO2 [M + H]
+
 
448.1846, found 448.1843. 
1-((2-((1R,3S,4S)-4-Methyl-3-(prop-1-en-2-yl)-4-vinylcyclohexyl)allyl)oxy)-3-(p-t
olylamino)propan-2-ol (6m): 
1
H NMR (300 MHz, CDCl3) δ 7.02 (d, J = 8.2 Hz, 2H), 
6.61 (d, J = 8.2 Hz, 2H), 5.84 (dd, J = 17.7, 10.6 Hz, 1H), 5.07 (s, 1H), 5.02 (s, 1H), 
4.96 (d, J = 3.5 Hz, 1H), 4.91 (s, 1H), 4.86 (s, 1H), 4.62 (s, 1H), 4.16 – 3.98 (m, 3H), 
3.61 – 3.39 (m, 2H), 3.38 – 3.26 (m, 1H), 3.16 (dd, J = 12.7, 7.3 Hz, 1H), 2.27 (s, 3H), 
2.12 – 1.96 (m, 2H), 1.74 (s, 3H), 1.73 – 1.55 (m, 3H), 1.56 – 1.43 (m, 3H), 1.04 (s, 
3H); 
13
C NMR (75 MHz, CDCl3) δ 149.70, 149.61, 147.05, 145.29, 129.29, 126.75, 
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113.07, 111.74, 110.05, 109.51, 73.24, 71.83, 68.56, 52.23, 46.87, 40.88, 39.41, 39.32, 
32.69, 26.61, 24.37, 19.92, 16.11; HRMS (ESI) calculated for C25H38NO2 [M + H]
+
 
384.2897, found 384.2899. 
1-((2-((1R,3S,4S)-4-Methyl-3-(prop-1-en-2-yl)-4-vinylcyclohexyl)allyl)oxy)-3-(nap
hthalen-1-ylamino)propan-2-ol (6n): 
1
H NMR (300 MHz, CDCl3) δ 7.84 – 7.66 (m, 
2H), 7.51 – 7.31 (m, 2H), 7.30 – 7.12 (m, 2H), 6.56 (d, J = 7.3 Hz, 1H), 5.71 (dd, J = 
17.8, 10.5 Hz, 1H), 4.98 (s, 1H), 4.93 (s, 1H), 4.84 (d, J = 2.0 Hz, 1H), 4.79 (d, J = 
2.7 Hz, 1H), 4.74 (s, 1H), 4.50 (s, 1H), 4.19 – 4.07 (m, 1H), 4.03 – 3.91 (m, 2H), 3.58 
– 3.45 (m, 2H), 3.39 (dd, J = 12.4, 4.1 Hz, 1H), 3.24 (dd, J = 12.4, 7.0 Hz, 1H), 2.03 – 
1.84 (m, 2H), 1.62 (s, 3H), 1.62 – 1.45 (m, 3H), 1.44 – 1.29 (m, 3H), 0.92 (s, 3H); 13C 
NMR (75 MHz, CDCl3) δ 149.65, 149.59, 147.05, 142.84, 133.83, 128.14, 126.01, 
125.33, 124.36, 123.36, 119.64, 117.55, 111.73, 110.29, 109.51, 104.45, 73.36, 72.06, 
68.42, 52.22, 46.75, 40.90, 39.38, 39.30, 32.70, 29.23, 26.62, 24.37, 16.10; HRMS 
(ESI) calculated for C28H38NO2 [M + H]
+
 420.2897, found 420.2893. 
1-(Benzylamino)-3-((2-((1R,3S,4S)-4-methyl-3-(prop-1-en-2-yl)-4-vinylcyclohexyl
)allyl)oxy)propan-2-ol (6o): 
1
H NMR (300 MHz, CDCl3) δ 7.35 – 7.11 (m, 5H), 5.74 
(dd, J = 17.7, 10.5 Hz, 1H), 4.94 (s, 1H), 4.89 (s, 1H), 4.85 (d, J = 3.3 Hz, 1H), 4.81 
(s, 1H), 4.75 (s, 1H), 4.51 (s, 1H), 3.90 (s, 2H), 3.90 – 3.80 (m, 1H), 3.79 – 3.69 (m, 
2H), 3.46 – 3.24 (m, 2H), 2.79 – 2.57 (m, 2H), 2.48 (s, 2H), 2.01 – 1.85 (m, 2H), 1.63 
(s, 3H), 1.62 – 1.46 (m, 3H), 1.45 – 1.30 (m, 3H), 0.93 (s, 3H); 13C NMR (75 MHz, 
CDCl3) δ 150.29, 150.15, 147.56, 139.56, 128.50, 128.21, 127.20, 112.18, 110.36, 
109.96, 73.70, 72.64, 68.81, 53.72, 52.74, 51.44, 41.35, 39.91, 39.81, 33.14, 27.07, 
24.83, 16.60; HRMS (ESI) calculated for C25H38NO2 [M + H]
+
 384.2897, found 
384.2895. 
1-((2-((1R,3S,4S)-4-Methyl-3-(prop-1-en-2-yl)-4-vinylcyclohexyl)allyl)oxy)-3-((2-
phenoxyethyl)amino)propan-2-ol (6p): 
1
H NMR (300 MHz, CDCl3) δ 7.25 – 7.15 (m, 
2H), 6.92 – 6.78 (m, 3H), 5.74 (dd, J = 17.8, 10.5 Hz, 1H), 4.95 (s, 1H), 4.90 (s, 1H), 
4.85 (d, J = 3.6 Hz, 1H), 4.80 (s, 1H), 4.75 (s, 1H), 4.51 (s, 1H), 4.01 (t, J = 5.1 Hz, 
2H), 3.93 (s, 2H), 3.90 – 3.80 (m, 1H), 3.44 – 3.30 (m, 2H), 2.98 (t, J = 5.1 Hz, 2H), 
2.83 – 2.61 (m, 4H), 2.02 – 1.88 (m, 2H), 1.63 (s, 3H), 1.62 – 1.46 (m, 3H), 1.45 – 
1.33 (m, 3H), 0.93 (s, 3H); 
13
C NMR (75 MHz, CDCl3) δ 158.18, 149.77, 149.65, 
147.07, 128.99, 120.45, 114.01, 111.68, 109.86, 109.46, 73.21, 72.06, 68.23, 66.44, 
52.24, 51.44, 48.21, 40.87, 39.42, 39.31, 32.65, 26.57, 24.34, 16.09; HRMS (ESI) 
calculated for C26H40NO3 [M + H]
+
 414.3003, found 414.3005. 
3,3'-(Piperazine-1,4-diyl)-bis(1-((2-((1R,3S,4S)-4-methyl-3-(prop-1-en-2-yl)-4-viny
lcyclohexyl)allyl)oxy)propan-2-ol) (6q): 
1
H NMR (300 MHz, CDCl3) δ 5.82 (dd, J = 
17.8, 10.5 Hz, 2H), 5.03 (s, 2H), 4.97 (s, 2H), 4.93 (d, J = 3.7 Hz, 2H), 4.88 (s, 2H), 
4.82 (s, 2H), 4.58 (s, 2H), 4.09 – 3.97 (m, 4H), 3.96 – 3.85 (m, 2H), 3.52 – 3.37 (m, 
4H), 3.21 (brs, 2H), 2.69 (s, 4H), 2.57 – 2.36 (m, 8H), 2.08 – 1.98 (m, 4H), 1.71 (s, 
6H), 1.69 – 1.58 (m, 6H), 1.53 – 1.41 (m, 6H), 1.01 (s, 6H); 13C NMR (75 MHz, 
CDCl3) δ 149.81, 149.65, 147.05, 111.67, 109.88, 109.45, 73.29, 71.83, 65.58, 60.21, 
52.72, 52.26, 40.85, 39.42, 39.30, 32.64, 26.55, 24.34, 16.10; HRMS (ESI) calculated 
for C40H67N2O4 [M + H]
+
 639.5095, found 639.5090. 
4.2. Pharmacology 
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4.2.1. In vitro antiproliferative assay 
SGC-7901, HeLa, U87, A549, and A549/DDP cells were purchased from Nanjing 
Key Gen Biotech Co. Ltd. (Nanjing, China). The cytotoxicity of the compounds was 
determined using MTT assay. Briefly, test cell lines were plated on 96-well plates at 
the density of 5×10
4
/well and incubated for 24 h at 37
o
C under an atomosphere of 5% 
CO2. The test compounds were dissolved in the culture medium with 0.5% DMSO at 
different concentrations and treated to the cells for another 72 h. The MTT (5 mg/mL 
in PBS) was added and incubated for another 4 h, the optical density was detected 
with a microplate reader at 490 nm. The IC50 values were calculated according to the 
dose-dependent curves. All the tests were repeated in at least three independent 
experiments. 
4.2.2. Cell cycle analysis 
SGC-7901 cells were incubated with 6q at indicated concentrations. After 
incubating for 72 h, the treated cells were trypsinized, washed with PBS and 
centrifuged. The collected cells were fixed by adding 70% ethanol at 4 
o
C overnight 
and incubated for 30 min in PBS containing 100 μL RNase A and 400 μL of 
propidium iodide. Analysis of the cell DNA content was performed with the system 
software (Cell Quest, BD Biosciences, USA). 
4.2.3. Apoptosis analysis 
SGC-7901 cells were seeded into 6-well plates and incubated at 37 
o
C for 24 h, and 
then treated with or without 6q at indicated concentrations for another 72 h. Cells 
were washed twice in PBS and resuspended in 500 μL Annexin V binding buffer. 
Then 5 μL of Annexin V-APC and 7-AAD were added successively and the mixture 
was incubated for 15 min under dark conditions at 25 C. Apoptosis was analyzed 
using a FACS Calibur flow cytometer (BectoneDickinson, San Jose, CA, USA). 
4.2.4. Mitochondrial membrane potential determination 
The mitochondrial membrane potential assay was performed according to the 
manufacturer’s instruction (KGA601, KeyGEN Biotech, Nanjing, China). Briefly, 
SGC-7901 cells were seeded into 6-well plates and incubated at 37 °C for 24 h, and 
then treated with or without 6q at indicated concentrations for another 72 h. Cells 
were washed in PBS, centrifuged, and then stained with JC-1 dye under dark 
conditions. The percentage of cells with healthy or collapsed mitochondrial 
membrane potentials was monitored by flow cytometry analysis (BectoneDickinson, 
San Jose, CA, USA). 
4.2.5. Western blotting 
SGC-7901 cells were incubated with different doses of 6q for 72 h. The cells were 
harvested and lysed using lysis buffer, and the solution was centrifuged. Then the 
protein concentrations were determined, and individual cell lysates (25 μg per lane) 
were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (10% 
gel, SDS-PAGE) and transferred onto nitrocellulose membranes. After being blocked 
with 5% fat-free milk, the target proteins in the membranes were probed with 
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monoclonal anti-Bax, anti-Bcl 2, anti-caspase 3, anti-caspase 9, anti-cytochrome C, 
anti-PARP and anti-GAPDH antibodies (KeyGEN Biotech, Nanjing, China), 
respectively. The bound antibodies were detected by horseradish peroxidase (HRP) 
conjugated second antibodies and visualized using an enhanced chemiluminescent 
reagent. The relative levels of each signaling event to control GAPDH were 
determined by densimetric scanning. 
4.2.6. Aqueous solubility assay 
The water solubility of 6a, 6q and β-elemene was determined by HPLC according 
to a previously published protocol [29]. Firstly, 10 mg of 6a, 6q or β-elemene was 
weighed and added to 1 mL of water, respectively. The suspensions were shaken at 25 
°C for 24 h and then centrifuged, and the supernatants were filtered. Aliquots (10 μL) 
of the supernatants were injected into the HPLC system equipped with a C18 
reverse-phase column (No. 03050804, 0.46 cm × 25 cm, Hanbang Tech., Huai’an, 
China). One-point calibration [30] was done by injecting 10 μL aliquots of the 
corresponding buffer solutions of 6a, 6q, or β-elemene with known concentrations. 
4.2.7. In vivo antitumor assay  
Antitumor activity against mice bearing H22 liver cancer was performed as 
described by Shi et al. [31] with a slight modification. Mice from Institute of Cancer 
Research with body weight 18-22 g were subcutaneously transplanted with H22 cells 
on the right oxter according to protocols of tumor transplant research. Incubated after 
one day, mice were weighted and divided randomly into 4 groups (8 mice/group). The 
groups were intravenously administered with β-elemene (60 mg/kg) or 6q (30 or 60 
mg/kg) in a vehicle of 10% DMF/2% Tween 80/88% saline once per day for 3 weeks. 
The mice were sacrificed after the treatments and the tumors were excised and 
weighed. The inhibition rate was calculated as follows: Tumor inhibitory ratio (%) = 
(1-average tumor weight of treated group/average tumor weight of control group) × 
100%. All procedures were performed following institutional approval in accordance 
with the NIH Guide for the Care and Use of Laboratory Animals. 
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